Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 2/3 4Phase 3 3Phase 1 2

Status

Completed 4Terminated 1

Sponsor Class

OTHER 25NIH 10INDUSTRY 5NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Dermatologic 2

Conditions

Carcinoma, Renal Cell 3Melanoma 2Neoplasms 1Margins of Excision 1Carcinoma 1Adenocarcinoma 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Interferon alpha-2 × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

NCT00613509 2016-04-14

Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Sanofi

Phase 2 Terminated
23 enrolled 14 charts
Dermatologic

Melanoma, Neoplasms

NCT00796757 2015-05-27

A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).

Hoffmann-La Roche

Phase 2 Completed
146 enrolled 13 charts
Genitourinary

Carcinoma, Renal Cell

NCT00520403 2014-10-13

A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.

Hoffmann-La Roche

Phase 2 Completed
25 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell

NCT00911443 2009-07-09

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

sigma-tau i.f.r. S.p.A.

Phase 2 Completed
488 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡